11-05 :: May/June 2011
nanotimes
Companies Facts
using 30nm class four gigabit (Gb) DDR3 DRAM chips.Samsung’s 30nm-class 4Gb DDR3 chip offers an approximate 50% increase in productivity over a 40nm-class 4Gb DDR3, and as a result is expected to achieve rapid market penetration. Samsung started producing monolithic 4Gb DDR3 DRAM devices based on 30nm-class technology in February, which is only one year after it started producing 40nm-class 4Gb DDR3 DRAM devices. Just two months later, it began to provide 16GB modules to a number of server system manufacturers. http://www.samsung.com/GreenMemory
Solazyme is offering 10,375,000 shares, and selling stockholders are offering 600,000 shares. Head- quartered in South San Francisco, USA, Solazyme, Inc. is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils. http://www.solazyme.com
S
tarpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) announced successful results
of a major phase 2 clinical study that demonstrated efficacy of VivaGel® vaginosis (BV).
for the treatment of bacterial Key Points: • VivaGel® • VivaGel® meets primary endpoint, demonstrating significant efficacy for treatment of BV; expected to avoid many shortcomings of existing therapies;
• Trial results support new patent filing which extends VivaGel®
S
olazyme‘s shares begun trading on the NASDAQ Global Select Market on May 27, 2011 under the ticker symbol “SZYM”.
In May 2011, the Compa- ny announced the pricing of its initial public offering of 10,975,000 shares of common stock at a price to the public of $18.00 per share. Of the shares of com- mon stock in the offering,
• BV prevention trial of VivaGel® 2011;
protection to at least 2032;
• Planning underway for Phase 3 trials for VivaGel® for BV treatment;
to commence Q3
• Addressable global market for BV treatment and prevention potentially exceeds $1B.
In May, Starpharma Holdings has signed a licence agreement with Okamoto Industries Inc (TSE: JP3192800005) in relation to the VivaGel®
43
-coated
condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market. http://www.starpharma.com